Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorTyra Biosciences, Inc

About this trial

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures

Able to understand and given written informed consent

Ta low grade

T1 low grade

Current or previous history of muscle invasive bladder cancer

Current or previous history of lymph node positive and/or metastatic bladder cancer

Evidence of pure squamous cell carcinoma, pure adenocarcinoma or pure undifferentiated carcinoma of the bladder

Currently receiving systemic cancer therapy (cytotoxic, immunotherapy, targeted)

90 Participants

are divided into 3 treatment groups

Australia

Epworth Freemasons-Victoria Parade3121, RichmondVictoria, Australia

Italy

Istituti Fisioterapici Ospitalieri (IFO) RomeItaly, Italy

Istituto Europeo di Oncologia20141, Milan Italy

Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara56126, Pisa Italy

Tyra Biosciences, Inc

Lead sponsor